Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma

Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma

Immune checkpoint inhibition (ICI)-based approaches have transformed the treatment landscape of numerous solid tumors. Glioblastoma (GBM) is an aggressive and almost universally fatal disease which is in need of novel treatment options, and combinations of immune checkpoint inhibitors, including dua...

Full description

Bibliographic Details
Main Authors: Rohit Thummalapalli, Thatcher Heumann, Julie Stein, Sarah Khan, David S. Priemer, Amy S. Duffield, John Laterra, Rima Couzi, Michael Lim, Matthias Holdhoff
Format: Article
Language:English
Published: Karger Publishers 2020-05-01
Series:Case Reports in Oncology
Subjects:
hemophagocytic lymphohistiocytosis
programmed cell death receptor-1
indoleamine-pyrrole 2,3-dioxygenase
immune checkpoint inhibition
immune-related adverse events
glioblastoma
Online Access:https://www.karger.com/Article/FullText/507281

Internet

https://www.karger.com/Article/FullText/507281

Similar Items